Please assess the completion status of the following clinical trial:

Trial Title: Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS747158

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provide signed IC prior to undergoing any study procedures~* Be male or nonpregnant female, between the ages of 18 to 75 years, inclusive~* Have:A rest/stress SPECT imaging study (either exercise or pharmacologic stress) within 21 days of enrollment, using 99mTc-labeled tracers and showing reversible ischemia~* Female patients must:~  * be nonlactating,~ * no longer have child-bearing potential, either because they are post-menopausal (defined as amenorrhea ≥ 12 consecutive months, or because they have undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy)~Exclusion Criteria:~* Presence of any condition that may disrupt and/or increase permeability of the BBB, including multiple sclerosis, Alzheimer's disease, Parkinson's disease, acute central nervous system (CNS) infection, CNS tumor, autoimmune disease affecting the CNS, or CNS inflammatory~* Current significant illness, pathology or physical examination or vital signs measurement-findings that could potentiate any adverse pharmacological event associated with a vasodilatory drug or any pathology that, in the opinion of the investigator, might confound the interpretation of the results of the study~* Known hypersensitivity to adenosine, dipyridamole or aminophylline~* Presence of any contraindications to exercise stress testing~* History of New York Heart Association Class III or IV Congestive Heart Failure (CHF)~* Any major surgery within 4 weeks prior to enrollment or planned within 2 weeks following completion of the 2-week telephone follow-up assessment~* Inability to tolerate IV medication.~* History of drug or alcohol abuse within the last year~* Participation in any investigational drug, device, or placebo study within 6 months prior to study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: dose range and dose interval (Type: EXPERIMENTAL): Patients to receive either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during pharmacological or exercise stress, over a 1-day or 2-day period.
- Cohort 2: Pharm&exercise stress Efficacy (Type: EXPERIMENTAL): Patients to receive 2 IV bolus injections of BMS747158:1 at rest and 1 at stress~For the Pharmacologic (Adenosine) Stress:~* Doses at rest to range between 2.9 and 3.4 mCi.~* Doses under stress to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~* Doses at rest were to range between 1.7 and 2.0 mCi.~* Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi.

Based on this trial design, predict the completion outcome and termination type (if applicable).